18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management

Esther Mena, Mehdi Taghipour, Sara Sheikhbahaei, Sahar Mirpour, Jennifer Xiao, Rathan M. Subramaniam

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose We aimed to evaluate the added value of performing fourth and subsequent follow-up 18F-FDG-PET/CT scans to clinical assessment and impact on the patient's management in patients with melanoma. Methods This was a retrospective study of 232 biopsy-proven melanoma patients who underwent 18F-FDG-PET/CT scans. Of these, 71 patients had 4 or more follow-up 18F-FDG-PET/CT scans after completion of primary treatment, with a total of 246 fourth or subsequent follow-up PET/CT scans. The added value of each follow-up PET/CT scan to the patient's clinical assessment and treatment management was established. Kaplan-Meier plots with a Mantel-Cox log-rank test were used to establish the patient's overall survival. Results Of the 246 fourth and subsequent follow-up PET/CT scans, 61% (150/246) were negative for malignancy, and 39.0% (96/246) were positive for recurrence/metastases. FDG-PET/CT was helpful in identifying malignancy in 6.5% of the scans performed without prior clinical suspicion, which ruled out malignancy in 28.5% of the scans obtained with prior clinical signs suggestive of recurrence or for secondary therapy assessment. The PET/CT scan resulted in change of the patient's management in approximately 16.7% (41/246) of the scans. Change in management was significantly greater in patients whose scans were done with prior clinical signs suggestive of malignancy, or for therapy assessment than without prior clinical suspicion (29.3% vs 4.1%; P < 0.0001). Statistically significant difference was seen in the overall survival between patients with at least 1 positive and all negative fourth and subsequent follow-up PET/CT scans at patient level (P = 0.001). Conclusions The fourth and subsequent 18F-FDG-PET/CT scans obtained after completion of primary treatment added value to clinical assessment in patients with melanoma. Patients with clinical signs suggestive of recurrence or metastases or being monitored for treatment response are more likely to benefit from the fourth or subsequent FDG PET/CT than those without prior clinical suspicion.

Original languageEnglish (US)
Pages (from-to)e403-e409
JournalClinical Nuclear Medicine
Volume41
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Fluorodeoxyglucose F18
Melanoma
Recurrence
Neoplasms
Therapeutics
Neoplasm Metastasis
Positron Emission Tomography Computed Tomography
Survival
Retrospective Studies

Keywords

  • F-FDG
  • clinical suspicion
  • melanoma
  • PET/CT
  • treatment management

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

18F-FDG PET/CT and Melanoma : Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management. / Mena, Esther; Taghipour, Mehdi; Sheikhbahaei, Sara; Mirpour, Sahar; Xiao, Jennifer; Subramaniam, Rathan M.

In: Clinical Nuclear Medicine, Vol. 41, No. 9, 01.09.2016, p. e403-e409.

Research output: Contribution to journalArticle

Mena, Esther ; Taghipour, Mehdi ; Sheikhbahaei, Sara ; Mirpour, Sahar ; Xiao, Jennifer ; Subramaniam, Rathan M. / 18F-FDG PET/CT and Melanoma : Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management. In: Clinical Nuclear Medicine. 2016 ; Vol. 41, No. 9. pp. e403-e409.
@article{e5b70b24f74f4d9d9a2b667eead2d8c3,
title = "18F-FDG PET/CT and Melanoma: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management",
abstract = "Purpose We aimed to evaluate the added value of performing fourth and subsequent follow-up 18F-FDG-PET/CT scans to clinical assessment and impact on the patient's management in patients with melanoma. Methods This was a retrospective study of 232 biopsy-proven melanoma patients who underwent 18F-FDG-PET/CT scans. Of these, 71 patients had 4 or more follow-up 18F-FDG-PET/CT scans after completion of primary treatment, with a total of 246 fourth or subsequent follow-up PET/CT scans. The added value of each follow-up PET/CT scan to the patient's clinical assessment and treatment management was established. Kaplan-Meier plots with a Mantel-Cox log-rank test were used to establish the patient's overall survival. Results Of the 246 fourth and subsequent follow-up PET/CT scans, 61{\%} (150/246) were negative for malignancy, and 39.0{\%} (96/246) were positive for recurrence/metastases. FDG-PET/CT was helpful in identifying malignancy in 6.5{\%} of the scans performed without prior clinical suspicion, which ruled out malignancy in 28.5{\%} of the scans obtained with prior clinical signs suggestive of recurrence or for secondary therapy assessment. The PET/CT scan resulted in change of the patient's management in approximately 16.7{\%} (41/246) of the scans. Change in management was significantly greater in patients whose scans were done with prior clinical signs suggestive of malignancy, or for therapy assessment than without prior clinical suspicion (29.3{\%} vs 4.1{\%}; P < 0.0001). Statistically significant difference was seen in the overall survival between patients with at least 1 positive and all negative fourth and subsequent follow-up PET/CT scans at patient level (P = 0.001). Conclusions The fourth and subsequent 18F-FDG-PET/CT scans obtained after completion of primary treatment added value to clinical assessment in patients with melanoma. Patients with clinical signs suggestive of recurrence or metastases or being monitored for treatment response are more likely to benefit from the fourth or subsequent FDG PET/CT than those without prior clinical suspicion.",
keywords = "F-FDG, clinical suspicion, melanoma, PET/CT, treatment management",
author = "Esther Mena and Mehdi Taghipour and Sara Sheikhbahaei and Sahar Mirpour and Jennifer Xiao and Subramaniam, {Rathan M.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1097/RLU.0000000000001275",
language = "English (US)",
volume = "41",
pages = "e403--e409",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - 18F-FDG PET/CT and Melanoma

T2 - Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management

AU - Mena, Esther

AU - Taghipour, Mehdi

AU - Sheikhbahaei, Sara

AU - Mirpour, Sahar

AU - Xiao, Jennifer

AU - Subramaniam, Rathan M.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Purpose We aimed to evaluate the added value of performing fourth and subsequent follow-up 18F-FDG-PET/CT scans to clinical assessment and impact on the patient's management in patients with melanoma. Methods This was a retrospective study of 232 biopsy-proven melanoma patients who underwent 18F-FDG-PET/CT scans. Of these, 71 patients had 4 or more follow-up 18F-FDG-PET/CT scans after completion of primary treatment, with a total of 246 fourth or subsequent follow-up PET/CT scans. The added value of each follow-up PET/CT scan to the patient's clinical assessment and treatment management was established. Kaplan-Meier plots with a Mantel-Cox log-rank test were used to establish the patient's overall survival. Results Of the 246 fourth and subsequent follow-up PET/CT scans, 61% (150/246) were negative for malignancy, and 39.0% (96/246) were positive for recurrence/metastases. FDG-PET/CT was helpful in identifying malignancy in 6.5% of the scans performed without prior clinical suspicion, which ruled out malignancy in 28.5% of the scans obtained with prior clinical signs suggestive of recurrence or for secondary therapy assessment. The PET/CT scan resulted in change of the patient's management in approximately 16.7% (41/246) of the scans. Change in management was significantly greater in patients whose scans were done with prior clinical signs suggestive of malignancy, or for therapy assessment than without prior clinical suspicion (29.3% vs 4.1%; P < 0.0001). Statistically significant difference was seen in the overall survival between patients with at least 1 positive and all negative fourth and subsequent follow-up PET/CT scans at patient level (P = 0.001). Conclusions The fourth and subsequent 18F-FDG-PET/CT scans obtained after completion of primary treatment added value to clinical assessment in patients with melanoma. Patients with clinical signs suggestive of recurrence or metastases or being monitored for treatment response are more likely to benefit from the fourth or subsequent FDG PET/CT than those without prior clinical suspicion.

AB - Purpose We aimed to evaluate the added value of performing fourth and subsequent follow-up 18F-FDG-PET/CT scans to clinical assessment and impact on the patient's management in patients with melanoma. Methods This was a retrospective study of 232 biopsy-proven melanoma patients who underwent 18F-FDG-PET/CT scans. Of these, 71 patients had 4 or more follow-up 18F-FDG-PET/CT scans after completion of primary treatment, with a total of 246 fourth or subsequent follow-up PET/CT scans. The added value of each follow-up PET/CT scan to the patient's clinical assessment and treatment management was established. Kaplan-Meier plots with a Mantel-Cox log-rank test were used to establish the patient's overall survival. Results Of the 246 fourth and subsequent follow-up PET/CT scans, 61% (150/246) were negative for malignancy, and 39.0% (96/246) were positive for recurrence/metastases. FDG-PET/CT was helpful in identifying malignancy in 6.5% of the scans performed without prior clinical suspicion, which ruled out malignancy in 28.5% of the scans obtained with prior clinical signs suggestive of recurrence or for secondary therapy assessment. The PET/CT scan resulted in change of the patient's management in approximately 16.7% (41/246) of the scans. Change in management was significantly greater in patients whose scans were done with prior clinical signs suggestive of malignancy, or for therapy assessment than without prior clinical suspicion (29.3% vs 4.1%; P < 0.0001). Statistically significant difference was seen in the overall survival between patients with at least 1 positive and all negative fourth and subsequent follow-up PET/CT scans at patient level (P = 0.001). Conclusions The fourth and subsequent 18F-FDG-PET/CT scans obtained after completion of primary treatment added value to clinical assessment in patients with melanoma. Patients with clinical signs suggestive of recurrence or metastases or being monitored for treatment response are more likely to benefit from the fourth or subsequent FDG PET/CT than those without prior clinical suspicion.

KW - F-FDG

KW - clinical suspicion

KW - melanoma

KW - PET/CT

KW - treatment management

UR - http://www.scopus.com/inward/record.url?scp=84976448198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976448198&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000001275

DO - 10.1097/RLU.0000000000001275

M3 - Article

C2 - 27355846

AN - SCOPUS:84976448198

VL - 41

SP - e403-e409

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 9

ER -